INBX Inhibrx, Inc.

Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biotechnology company with a differentiated and sustainable product portfolio.

$11.58  +0.23 (2.03%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/19/2020
Outstanding shares:  39,037,343
Average volume:  493,725
Market cap:   $443,073,843
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK1MBC3
Valuation   (See tab for details)
PE ratio:   -4.82
PB ratio:   16.52
PS ratio:   61.74
Return on equity:   -342.72%
Net income %:   -1,306.02%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy